Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | SRC | P12931 | 1/20 | 0.50 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.47 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 7/20 | 0.45 |
| ▸ | LMNA | P02545 | 4/20 | 0.45 |
| ▸ | GAA | P10253 | 3/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18956077 | 0.85 | CA12 (0.43) | RAB9ASMN1; SMN2NPC1SRCDYRK1A | |
| SCHEMBL1788065 | 0.81 | RAB9A (0.41) | RAB9ASMN1; SMN2NPC1MAPTLMNA | |
| SCHEMBL2181717 | 0.81 | SIRT5 (0.57) | RAB9ASMN1; SMN2NPC1PDPK1MAPT | |
| SCHEMBL22528923 | 0.79 | ADORA1 (0.39) | RAB9ASMN1; SMN2NPC1SRCKMT2A | |
| SCHEMBL22528845 | 0.77 | CHEK1 (0.59) | RAB9ASMN1; SMN2NPC1DYRK1APDPK1 | |
| SCHEMBL737611 | 0.74 | TNK2 (0.52) | RAB9ASMN1; SMN2NPC1SRCDYRK1A | |
| SCHEMBL22528854 | 0.74 | PDPK1 (0.40) | PDPK1GAAHTTHPGDPARP1 | |
| SCHEMBL22528928 | 0.74 | PARP1 (0.37) | RAB9ANPC1PDPK1MAPTLMNA | |
| SCHEMBL14013962 | 0.73 | PARP1 (0.44) | RAB9ASMN1; SMN2NPC1MAPTALDH1A1 | |
| SCHEMBL20911745 | 0.71 | NPC1 (0.54) | RAB9ASMN1; SMN2NPC1SRCDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108473434-B | Substituted quinolone derivative or pharmaceutically acceptable salt or stereoisomer thereof, and medicinal composition and application thereof | 上海海和药物研究开发股份有限公司 | 2021-11-23 | — | — | CN | disclosed |
| EP-3339294-B1 | QUINOLONE DERIVATIVE, PHARMACEUTICAL ACCEPTABLE SALT, OR STEREOISOMER THEREOF AS AXL INHIBIOTOR | SHANGHAI HAIHE PHARMACEUTICAL CO LTD (CN) | 2021-04-14 | — | — | EP | disclosed |
| US-10683278-B2 | Substituted quinolone derivatives, or pharmaceutically acceptable salts or stereoisomers thereof, and pharmaceutical compositions and use thereof | SHANGHAI HAIHE PHARMACEUTICAL CO., LTD. (CN) | 2020-06-16 | — | — | US | disclosed |
| US-10683278-B2 | Substituted quinolone derivatives, or pharmaceutically acceptable salts or stereoisomers thereof, and pharmaceutical compositions and use thereof | SHANGHAI HAIHE PHARMACEUTICAL CO., LTD. (CN) | 2020-06-16 | — | — | US | disclosed |
| US-20180265496-A1 | SUBSTITUTED QUINOLONE DERIVATIVES, OR PHARMACEUTICALLY ACCEPTABLE SALTS OR STEREOISOMERS THEREOF, AND PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | JINAN UNIVERSITY (CN) | 2018-09-20 | — | — | US | disclosed |
| CN-108473434-A | Substituted quinolone analog derivative or its pharmaceutically acceptable salt or stereoisomer and its Pharmaceutical composition and application | 暨南大学 | 2018-08-31 | — | — | CN | disclosed |
| EP-3339294-A1 | PHARMACEUTICAL COMPOSITION AND APPLICATION REPLACING QUINOLONE DERIVATIVE, PHARMACEUTICAL ACCEPTABLE SALT, OR STEREOISOMER | Jinan University (CN) | 2018-06-27 | — | — | EP | disclosed |
| WO-2017028797-A1 | PHARMACEUTICAL COMPOSITION AND APPLICATION REPLACING QUINOLONE DERIVATIVE, PHARMACEUTICAL ACCEPTABLE SALT, OR STEREOISOMER | 暨南大学 | 2017-02-23 | — | — | WO | disclosed |
| EP-2838901-B1 | 6-(4-(1-AMINO-3-HYDROXYCYCLOBUTYL)PHENYL)-5-PHENYL(FURO, THIENO OR PYRROLO)[2,3-D]PYRIMIDIN-4-ONE DERIVATIVES FOR THE TREATMENT OF CANCER | ALMAC DISCOVERY LTD (GB) | 2016-11-02 | — | — | EP | disclosed |
| US-9156853-B2 | AKT inhibitor compounds for treatment of cancer | ALMAC DISCOVERY LIMITED (GB) | 2015-10-13 | — | — | US | disclosed |
| WO-2008131858-A2 | USE OF ACYCLICALLY SUBSTITUTED FUROPYRIMIDINE DERIVATIVES FOR TREATING PULMONARY ARTERIAL HYPERTONIA | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-11-06 | — | — | WO | disclosed |
| WO-2008131858-A2 | USE OF ACYCLICALLY SUBSTITUTED FUROPYRIMIDINE DERIVATIVES FOR TREATING PULMONARY ARTERIAL HYPERTONIA | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-11-06 | — | — | WO | disclosed |
| WO-2008131859-A2 | USE OF CYCLICALLY SUBSTITUTED FUROPYRIMIDINE DERIVATIVES FOR TREATING PULMONARY ARTERIAL HYPERTONIA | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-11-06 | — | — | WO | disclosed |
| EP-1966217-A1 | NOVEL, ACYCLIC SUBSTITUTED FUROPYRIMIDINE DERIVATIVES AND USE THEREOF FOR TREATING CARDIOVASCULAR DISEASES | Bayer HealthCare AG (DE) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007079862-A1 | NOVEL, ACYCLIC SUBSTITUTED FUROPYRIMIDINE DERIVATIVES AND USE THEREOF FOR TREATING CARDIOVASCULAR DISEASES | BAYER HEALTHCARE AG (DE) | 2007-07-19 | — | — | WO | disclosed |
| WO-2007079862-A1 | NOVEL, ACYCLIC SUBSTITUTED FUROPYRIMIDINE DERIVATIVES AND USE THEREOF FOR TREATING CARDIOVASCULAR DISEASES | BAYER HEALTHCARE AG (DE) | 2007-07-19 | — | — | WO | disclosed |
| WO-2007079861-A1 | NOVEL, CYCLIC SUBSTITUTED FUROPYRIMIDINE DERIVATIVES AND USE THEREOF FOR TREATING CARDIOVASCULAR DISEASES | BAYER HEALTHCARE AG (DE) | 2007-07-19 | — | — | WO | disclosed |
| EP-1768986-A2 | FURANOPYRIMIDINES | Amgen Inc. (US) | 2007-04-04 | — | — | EP | disclosed |
| US-20060040961-A1 | Furanopyrimidines | AMGEN INC. | 2006-02-23 | — | — | US | disclosed |
| WO-2006004658-A2 | FURANOPYRIMIDINES | AMGEN INC. (US) | 2006-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180265496-A1 | SUBSTITUTED QUINOLONE DERIVATIVES, OR PHARMACEUTICALLY ACCEPTABLE SALTS OR STEREOISOMERS THEREOF, AND PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | NRAS, AXL, ABL1 | RAB9A 757/4885SMN1; SMN2 4166/4885NPC1 3553/4885 |
| US-20060040961-A1 | Furanopyrimidines | TYMS, IDO1, NFATC1 | RAB9A 3209/4885SMN1; SMN2 1350/4885NPC1 4144/4885 |
| US-10683278-B2 | Substituted quinolone derivatives, or pharmaceutically acceptable salts or stereoisomers thereof, and pharmaceutical compositions and use thereof | NRAS, AXL, ABL1 | RAB9A 757/4885SMN1; SMN2 4166/4885NPC1 3553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.